This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 23 Jul 2025

Praluent® (alirocumab) Administration

Author: Sanofi

Editorial Team

  
Praluent logo

Prescribing Information (UK)

Praluent® can be injected subcutaneously into the thigh, abdomen or upper arm. Patients should rotate the injection site with each injection.1

Ease of use assessed as ≥9.8 out of 10 in all assessments for both devices*2

300 mg Q4W

75 mg and 150 mg Q2W

*Study of 69 patients who randomly received unsupervised, self-administered alirocumab 300 mg via 1 x 300 mg injection with the SYDNEY device (n=35) or 2 x 150 mg injections with the currently approved auto-injector (n=34). Possible answers ranged from 1 (very dissatisfied) to 10 (very satisfied).
**Evaluated in a cross-sectional, non-interventional study involving 151 patients enrolled in Praluent® phase 3 trials.
SmPC=summary of product characteristics.

Up to 30 days out of the fridge1

  • Store in a refrigerator (2°C to 8°C). Do not freeze
  • PRALUENT® can be kept outside a refrigerator below 25°C and protected from light for a single period not exceeding 30 days
  • After removal from the refrigerator, the medicinal product must be used within 30 days or discarded.
  • Keep the pen in the outer carton in order to protect from light.

Although many patients requiring lipid lowering therapies are not experienced with self-injected medication, in a real world study, results indicated that the pre-filled pen was well-accepted by patients.6

Dosage information

The recommended alirocumab doses are 75 mg once every 2 weeks, 150 mg once every 2 weeks, 300 mg once every 4 weeks (monthly), administered subcutaneously. All doses may be used for initiation of treatment.

The dose of alirocumab can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response to treatment. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). Intense LDL-C reduction is expected with alirocumab 150 mg once every 2 weeks and 300 mg once every 4 weeks (monthly), where 150 mg once every 2 weeks is the maximum dose (see section 5.1 of the SmPC).

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed July 2025.
  2. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.
  3. Praluent Patient information lealfet 150mg. July 2025.
  4. Praluent Patient information leaflet 300mg. July 2025.
  5. Tatlock S, et al. Value Health 2017;20:430–440.
  6. Roth E, et al. Clin Ther 2015;37(9):1945–1954.

MAT-XU-2503036 (v1.0) Date of Preparation: July 2025  

Related Content